Skip to main content
Log in

Effect of probenecid on isofezolac kinetics

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The interaction between isofezolac and probenecid has been studied with the aid of a specific HPLC assay for isofezolac in plasma and urine. 8 healthy adult volunteers received a single 40 mg oral dose of isofezolac before and after 3 days of loading with 0.5 g probenecid t.i.d. There was an increase in the maximum plasma isofezolac concentration from 2.44 to 3.38 µg · ml−1 when probenecid was given. The AUC of isofezolac in plasma increased from 6.73 to 11.28 µg · h · ml−1. After the last dose in a 7 day treatment with 40 mg isofezolac t.i.d., there was an increase in the maximum plasma isofezolac level from 2.84 to 4.96 µg · ml−1 when probenecid was given. The rate of absorption of isofezolac was not affected. An increase in the AUC of isofezolac in plasma was observed from 11.74 to 26.34 µg · h · ml−1. The major effect of probenecid on isofezolac metabolism was a 50% reduction in total isofezolac (free+conjugates) excreted inurine. Because of this interaction, patients given isofezolac combined with probenecid will have a higher steady-state plasma level of isofezolac than when probenecid is not administered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Baber N, Halliday L, Sibeon R, Littler T, L'E Orme M (1978) The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. Clin Pharmacol Ther 24: 298–307

    Google Scholar 

  • Bannier A, Brazier JL (1980) Determination of isofezolac in biological fluids by reversed-phase liquid column chromatography. J Chromatogr 182: 369–377

    Google Scholar 

  • Bannier A, Brazier JL, Soubeyrand J (1982) Dosage de l'isofezolac dans les milieux biologiques. Applications à la pharmacocinétique. 1er Congrès Européen de Biopharmacie et Pharmacocinétique, Lavoisier (ed.), Paris, pp. 201–209

  • Mizoule J, Lefur G, Uzan A (1979) Study of two new non-steroid anti-inflammatory drugs having a pyrazole structure (LM 22070 and LM 22102). Arch Int Pharmacodyn 238: 305–332

    Google Scholar 

  • Runkel R, Mroszczak E, Chaplin M, Sevelius H, Segre E (1978) Naproxen-Probenecid interaction. Clin Pharmacol Ther 24: 706–713

    Google Scholar 

  • Upton RA, Williams RL, Buskin JN, Matthew-Jones R (1982) Effects of probenecid on ketoprofen kinetics. Clin Pharmacol Ther 31: 705–712

    Google Scholar 

  • Veenendaal JR, Brooks AM, Meffin PJ (1981) Probenecid-clofibrate interaction. Clin Pharmacol Ther 29: 351–358

    Google Scholar 

  • Weiner IM, Washington JA, Mudge GM (1969) On the mecanism of action of probenecid on renal tubular excretion. Bull Johns Hopkins Hosp 166: 333–346

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bannier, A., Comet, F., Soubeyrand, J. et al. Effect of probenecid on isofezolac kinetics. Eur J Clin Pharmacol 28, 433–437 (1985). https://doi.org/10.1007/BF00544363

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00544363

Key words

Navigation